Simulations Plus's 15min chart shows KDJ Golden Cross, Bullish Marubozu.

Simulations Plus's 15-minute chart has recently triggered a Golden Cross pattern, accompanied by a Bullish Marubozu candle at 08/29/2025 11:45. This indicates a shift in momentum towards an upward trend, potentially leading to further price increases. The control of the market is currently in the hands of buyers, and it is likely that bullish momentum will continue.

Simulations Plus, Inc. (NASDAQ: SLP) has recently received a consensus recommendation of "Moderate Buy" from analysts, according to a report from MarketBeat [1]. The average 12-month price target among the seven brokerages covering the company is $26.50, reflecting optimism about the technology company's future prospects.

The company's most recent earnings report, released on July 14, 2025, showed earnings per share (EPS) of $0.45, surpassing the consensus estimate of $0.26. However, revenue of $20.36 million fell short of expectations of $22.83 million. Despite this, institutional investors have shown strong interest in Simulations Plus, holding 78.08% of its stock, with notable increases in holdings by firms like Conestoga Capital Advisors and Ameriprise Financial [1].

In a significant technical development, Simulations Plus's 15-minute chart recently triggered a Golden Cross pattern, accompanied by a Bullish Marubozu candle on August 29, 2025, at 11:45 [1]. This pattern, which occurs when a short-term moving average crosses above a longer-term moving average, often signals a shift in momentum towards an upward trend. The Bullish Marubozu candle, characterized by a large body with no upper or lower shadows, further indicates strong bullish sentiment. This technical setup suggests that the control of the market is currently in the hands of buyers, and it is likely that bullish momentum will continue.

Simulations Plus develops drug discovery and development software, operating through two segments: Software and Services. Its products, including GastroPlus, DDDPlus, and MembranePlus, utilize artificial intelligence and machine learning to simulate molecular properties and drug interactions. The company's revenue for the quarter ending July 14, 2025, was up 9.8% compared to the same period last year, reflecting growth in its core business [1].

While Simulations Plus currently has a Moderate Buy rating among analysts, top-rated analysts believe there are five stocks that are better buys, as identified by MarketBeat [1]. Despite this, the recent technical momentum shift and analyst recommendations suggest that Simulations Plus remains an attractive investment opportunity for those seeking exposure to the drug discovery and development sector.

References:
[1] https://www.marketbeat.com/instant-alerts/simulations-plus-inc-nasdaqslp-receives-consensus-recommendation-of-moderate-buy-from-analysts-2025-08-20/